Literature DB >> 20975803

Antihemophilic factor [recombinant], formulated with sucrose.

.   

Abstract

Entities:  

Year:  2010        PMID: 20975803      PMCID: PMC2957727     

Source DB:  PubMed          Journal:  P T        ISSN: 1052-1372


× No keyword cloud information.
  21 in total

1.  Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis.

Authors:  G C White; F Rosendaal; L M Aledort; J M Lusher; C Rothschild; J Ingerslev
Journal:  Thromb Haemost       Date:  2001-03       Impact factor: 5.249

2.  Prophylactic treatment for prevention of joint disease in hemophilia--cost versus benefit.

Authors:  Goris Roosendaal; Floris Lafeber
Journal:  N Engl J Med       Date:  2007-08-09       Impact factor: 91.245

Review 3.  Factor VIII structure and function.

Authors:  P J Fay
Journal:  Thromb Haemost       Date:  1993-07-01       Impact factor: 5.249

4.  Factor VIII gene inversions in severe hemophilia A: results of an international consortium study.

Authors:  S E Antonarakis; J P Rossiter; M Young; J Horst; P de Moerloose; S S Sommer; R P Ketterling; H H Kazazian; C Négrier; C Vinciguerra; J Gitschier; M Goossens; E Girodon; N Ghanem; F Plassa; J M Lavergne; M Vidaud; J M Costa; Y Laurian; S W Lin; S R Lin; M C Shen; D Lillicrap; S A Taylor; S Windsor; S V Valleix; K Nafa; Y Sultan; M Delpech; C L Vnencak-Jones; J A Phillips; R C Ljung; E Koumbarelis; A Gialeraki; T Mandalaki; P V Jenkins; P W Collins; K J Pasi; A Goodeve; I Peake; F E Preston; M Schwartz; E Scheibel; J Ingerslev; D N Cooper; D S Millar; V V Kakkar; F Giannelli; J A Naylor; E F Tizzano; M Baiget; M Domenech; C Altisent; J Tusell; M Beneyto; J I Lorenzo; C Gaucher; C Mazurier; K Peerlinck; G Matthijs; J J Cassiman; J Vermylen; P G Mori; M Acquila; D Caprino; H Inaba
Journal:  Blood       Date:  1995-09-15       Impact factor: 22.113

5.  Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy--International Kogenate-FS Study Group.

Authors:  T C Abshire; H H Brackmann; I Scharrer; K Hoots; C Gazengel; J S Powell; E Gorina; E Kellermann; E Vosburgh
Journal:  Thromb Haemost       Date:  2000-06       Impact factor: 5.249

Review 6.  Structure and function of the factor VIII gene and protein.

Authors:  Arthur R Thompson
Journal:  Semin Thromb Hemost       Date:  2003-02       Impact factor: 4.180

Review 7.  Haemophilias A and B.

Authors:  Paula H B Bolton-Maggs; K John Pasi
Journal:  Lancet       Date:  2003-05-24       Impact factor: 79.321

Review 8.  Hemophilia A--from basic science to clinical practice.

Authors:  Jens Klinge; Natalya M Ananyeva; Charlotte A E Hauser; Evgueni L Saenko
Journal:  Semin Thromb Hemost       Date:  2002-06       Impact factor: 4.180

9.  Changes in the life expectancy of patients with severe haemophilia A in Finland in 1930-79.

Authors:  E Ikkala; T Helske; G Myllylä; H R Nevanlinna; P Pitkänen; V Rasi
Journal:  Br J Haematol       Date:  1982-09       Impact factor: 6.998

Review 10.  How do you treat bleeding disorders with desmopressin?

Authors:  Bülent Ozgönenel; Madhvi Rajpurkar; Jeanne M Lusher
Journal:  Postgrad Med J       Date:  2007-03       Impact factor: 2.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.